Quarterly report pursuant to Section 13 or 15(d)

Condensed Statement of Changes in Stockholders??? Equity (Unaudited)

v3.23.3
Condensed Statement of Changes in Stockholders’ Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021   7,809,912    
Beginning balance at Dec. 31, 2021 $ 13,410 $ 1 $ 22,633 $ (9,224)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock based compensation expense 774   774  
Sale of Common Stock, net of issuance costs (in shares)   136,025    
Sale of Common Stock, net of issuance costs 804   804  
Stock issuance upon exercise of stock options (in shares)   33,683    
Stock issuance upon exercise of stock options 2   2  
Stock issuance upon vesting of restricted stock awards (in shares)   21,250    
Net loss (9,250)     (9,250)
Ending balance (in shares) at Sep. 30, 2022   8,000,870    
Ending balance at Sep. 30, 2022 5,740 $ 1 24,213 (18,474)
Beginning balance (in shares) at Jun. 30, 2022   7,982,008    
Beginning balance at Jun. 30, 2022 8,968 $ 1 23,862 (14,895)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock based compensation expense 351   351  
Stock issuance upon exercise of stock options (in shares)   5,112    
Stock issuance upon vesting of restricted stock awards (in shares)   13,750    
Net loss (3,579)     (3,579)
Ending balance (in shares) at Sep. 30, 2022   8,000,870    
Ending balance at Sep. 30, 2022 $ 5,740 $ 1 24,213 (18,474)
Beginning balance (in shares) at Dec. 31, 2022 8,009,743 8,009,743    
Beginning balance at Dec. 31, 2022 $ 2,374 $ 1 24,559 (22,186)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock based compensation expense 2,021   2,021  
Sale of Common Stock, net of issuance costs (in shares)   17,872,955    
Sale of Common Stock, net of issuance costs $ 24,764 $ 2 24,762  
Stock issuance upon exercise of stock options (in shares) 288,001 180,072    
Stock issuance upon exercise of stock options $ 214   214  
Stock issuance upon vesting of restricted stock awards (in shares)   255,220    
Stock issuance upon exercise of warrants (in shares) 1,471 7,292    
Stock issuance upon exercise of warrants $ 16   16  
Net loss $ (10,760)     (10,760)
Ending balance (in shares) at Sep. 30, 2023 26,325,282 26,325,282    
Ending balance at Sep. 30, 2023 $ 18,629 $ 3 51,572 (32,946)
Beginning balance (in shares) at Jun. 30, 2023   25,990,516    
Beginning balance at Jun. 30, 2023 21,062 $ 3 50,535 (29,476)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock based compensation expense 926   926  
Stock issuance upon exercise of stock options (in shares)   92,046    
Stock issuance upon exercise of stock options 111   111  
Stock issuance upon vesting of restricted stock awards (in shares)   242,720    
Net loss $ (3,470)     (3,470)
Ending balance (in shares) at Sep. 30, 2023 26,325,282 26,325,282    
Ending balance at Sep. 30, 2023 $ 18,629 $ 3 $ 51,572 $ (32,946)